Ansa Biotechnologies Raises $71.5M Series C for Long DNA That AI Biology Can Actually Test
AI can design a protein in an afternoon. Getting the DNA to test it can take weeks, or never arrive at all. That gap is the business of Ansa Biotechnologies, an Emeryville, California company that closed a $71.5M oversubscribed Series C, announced on Wednesday November 18 (Business Wire, 01:09 UTC November 19). It missed our last two editions, so this is a catch-up on a quiet Saturday. Total raised is now $211M. Release: https://www.biospace.com/press-releases/ansa-biotechnologies-raises-71-5-million-in-oversubscribed-series-c-round-to-scale-guaranteed-dna-synthesis
Blue Water Life Science Advisors led. New investors are Illumina Ventures, BEVC, Lightscape Partners and Agent Capital; existing backers Cerberus Ventures, Fall Line Capital, Dauntless Ventures and Altitude Life Science Ventures came back. Valuation was not disclosed. The board gets three new names: Nick Naclerio, founding partner of Illumina Ventures, Brad Crutchfield, former chief commercial officer of 10x Genomics, and Blue Water founder Nate Cornell. The money goes to more capacity and more customers in drug discovery, cell and gene therapy, vaccines and agrigenomics. Capacity already went up 4x in the past year.
What is enzymatic DNA synthesis? The old way builds DNA one letter at a time with harsh chemistry, and every step has a small error rate, so long sequences pile up mistakes and you get stuck at short pieces that have to be stitched together. Ansa uses an enzyme, the same kind of tool cells use to write DNA, which is gentler and can go longer and handle the ugly sequences, like repeats, that chemistry chokes on. The product: sequence-perfect clonal DNA up to 50 kilobases plus verified linear fragments. And a very unbiotech promise: if the order misses its guaranteed ship date, the whole order is free.
The reason this belongs on an AI site is in the release itself: conventional synthesis "can prevent researchers from translating computational designs into physical DNA and generating the experimental data needed to validate and refine AI models." Naclerio put it more bluntly: "The full potential of AI-enabled biology depends on the ability to build and test what computational models design." The design side of biology got 100x faster. The wet lab is the bottleneck now, and whoever makes the build-and-test loop predictable owns the slow half of the loop. A ship-date guarantee sounds like logistics. For an AI lab running design rounds, it is the clock speed.
← Back to all articles
Blue Water Life Science Advisors led. New investors are Illumina Ventures, BEVC, Lightscape Partners and Agent Capital; existing backers Cerberus Ventures, Fall Line Capital, Dauntless Ventures and Altitude Life Science Ventures came back. Valuation was not disclosed. The board gets three new names: Nick Naclerio, founding partner of Illumina Ventures, Brad Crutchfield, former chief commercial officer of 10x Genomics, and Blue Water founder Nate Cornell. The money goes to more capacity and more customers in drug discovery, cell and gene therapy, vaccines and agrigenomics. Capacity already went up 4x in the past year.
What is enzymatic DNA synthesis? The old way builds DNA one letter at a time with harsh chemistry, and every step has a small error rate, so long sequences pile up mistakes and you get stuck at short pieces that have to be stitched together. Ansa uses an enzyme, the same kind of tool cells use to write DNA, which is gentler and can go longer and handle the ugly sequences, like repeats, that chemistry chokes on. The product: sequence-perfect clonal DNA up to 50 kilobases plus verified linear fragments. And a very unbiotech promise: if the order misses its guaranteed ship date, the whole order is free.
The reason this belongs on an AI site is in the release itself: conventional synthesis "can prevent researchers from translating computational designs into physical DNA and generating the experimental data needed to validate and refine AI models." Naclerio put it more bluntly: "The full potential of AI-enabled biology depends on the ability to build and test what computational models design." The design side of biology got 100x faster. The wet lab is the bottleneck now, and whoever makes the build-and-test loop predictable owns the slow half of the loop. A ship-date guarantee sounds like logistics. For an AI lab running design rounds, it is the clock speed.
Comments